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inTRODUCTiOn
We have previously shown that monomeric c-reactive 
protein (mcrP) was dramatically over-expressed in the 
brain extracellular matrix (ecM) of patients following 
acute ischaemic stroke (1). in addition, mcrP, unlike the 
native pentameric molecule (pcrP), stimulated aberrant 
angiogenesis in vitro, induced phosphorylation of tau by 
neurons and tau-244-372 aggregation in vitro and following 
injection into the hippocampus of mice, directly resulted 
in cognitive and memory decline similar to that seen in a 
model of alzheimer’s disease (ad) (tg x 3) (2). 
mcrP also co-localised with cd105 in microvessels 
suggesting angiogenesis. Phospho-arrays/Western blotting 
identified signalling activation in both endothelial cells and 
neurons through p-irS-1, p-tau and p-erK1/2-which was 
blocked following pre-incubation with mcrP-antibody 
suggesting that the antibody could have therapeutic potential. 
mcrP increased vascular monolayer permeability and 
gap junctions, increased ncaM expression and produced 
haemorrhagic angiogenesis in mouse matrigel implants and 
clearly has abnormal effects on the vascular system.
Previously, Strang et al. (3) demonstrated that aβ plaques 
generated in vitro were able to dissociate pcrP to mcrP, 
probably produced de-novo within the brain ecM, whilst 
in vivo, more mcrP was identified within frontal cortex 
regions in victims of ad than normal control brains 
suggesting a possible pathological or regulatory role in 
development of the disease. 
cerebrovascular disease, neurovascular dysfunction and 
cerebral blood flow abnormalities are now recognised as 
critical influences in the pathophysiological development of 
ad, damaged, blocked or in patent vessels having a severe 
effect on the function of local neurovascular units (with 
approximately 80% of ad brains at post-mortem shown to 
have significant vascular abnormalities).
damage to the deep penetrating vessels within the brain 
such as following lacunar stroke, ischaemic stroke or 
head trauma, may lower the threshold for development 
of vascular and other (mixed) dementia, particularly in 
younger patients (4, 5). 
ABSTRACT
Objective: We have previously shown that monomeric-c-reactive protein is deposited in significant quantities within the brain parenchyma after 
stroke. Since we have recently identified a possible role of this protein in supporting neurodegeneration and aberrant vascular development, 
we identified a small group of post-mortem brain samples from individuals who had alzheimer’s disease and evidence of tissue infarction/
micro-infarction on histological examination. 
Material and Method: We used immunohistochemistry staining to identify the monomeric-c-reactive protein expressed in the infarcted brain 
tissues. 
Results: We showed that monomeric-c-reactive protein deposition was highest in those regions affected by stroke or vascular disruption, and 
that within those same areas, there was more interaction and co-localization between major classical proteins of neurodegeneration (β-amyloid 
and tau). 
Conclusion: We hypothesise that vascular disruption and concomitant release of monomeric-c-reactive protein within the brain tissue could 
exacerbate ongoing neurological damage via stimulation of neuro-inflammation and from direct consequences of its action on both neuronal 
and vascular cells.   
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Here, we investigated the possible link between mcrP 
deposition and localization within the brain and indicators 
of previous stroke or vascular disruption and dementia. 
MATeRiAl and MeTHODS 
Samples of brain tissue were obtained from the Bristol 
Brain Bank, where from a cohort of 10 individuals, 
3 were identified as having concomitant histological 
evidence of ad and stroke (assessed independently and 
also by our clinical neurologist; table i), and a clinical 
registered history of ad. the ad cases all had a history of 
progressive dementia and were selected on the basis of a 
diagnosis according to consortium to establish a registry 
for alzheimer’s disease (cerad) of ‘definite ad’ (6). 
ad neuropathological change was considered a sufficient 
explanation for the dementia in all cases. 
Full ethical approval was obtained for the use of tissue 
samples as detailed by the South West dementia Brain 
Bank (SWdBB) and obtained from them.
Mouse monoclonal antibody to human mcrP sub-unit 
(M8c10) was obtained from dr L.a, and was stated as 
previously (2). Mouse monoclonal antibodies to p-tau 
and β-amyloid were purchased from abcam (UK). 
Standard immunohistochemistry staining was carried 
out according to the protocols and fully characterized as 
described previously (1). Paraffin processed sections from 
frontal, parietal and temporal regions were examined for 
expression of mcrP (mouse monoclonal; 1:10 dilution; 
blue-grey colour). these were our own characterized 
antibodies, and originally a gift from dr Larry Potempa, 
roosevelt University, USa (1). in addition co-staining 
(double immunohistochemical labelling for key marker 
proteins of neurodegeneration (rabbit polyclonal p-tau 
and β-amyloid; used at 1:500 dilution; brown) with ViP 
VectaStain-eLite-vector HrP kits (from Vector labs.
com) was carried out. Particular attention was given to 
analysis of staining patterns associated with areas of tissue 
showing evidence of inflammation, vascular damage and 
regions showing morphological appearance of micro-
infarct or other previous stroke. 
Staining patterns and intensity were observed by an 
independent neuropathologist in a blinded fashion. total 
staining was not quantified but overall expression in 
different regions and by specific recognisable cell types 
over the whole region were characterised using our double 
size sections. For plaque numbers and numbers of neurons 
positively stained, counting of 10 × fields of view at × 100 
per section of three sections was employed. a distinction 
between strong (intense) and weak staining was also made.
ReSUlTS
immunohistochemical Findings
the staining pattern revealed that mcrP was almost absent 
from normal looking regions of brain tissue without signs 
of neurodegeneration or previous tissue insult. occasional 
blood vessels, neurons and glia of brain tissue showed 
positive mcrP staining. However, mcrP expression 
increased in the areas demonstrating typical ad pathology 
(i.e. amyloid deposits and neurofibrillary tangles). in these 
later areas, mcrP was mainly localized to blood vessels and 
neurons with a smaller expression within glia. 
mcrP expression was most abundantly present in areas 
of microinfarction (and adjacent regions) in both grey 
and white matter, whilst in relatively normal looking 
areas, expression was weak or none-existent (Figure 1a). 
mcrP expression was not seen in normal looking regions 
and hence quantification of the extent of staining was not 
attempted.
Β-amyloid staining and co-localization: areas with 
evidence of previous microinfarctions concomitantly 
expressed more β-amyloid. Some of the amyloid plaques 
were close to adjacent blood vessels where mcrP expression 
was abundant (Figure 1B). the co-localization between 
mcrP and β-amyloid in blood vessels was also mainly 
seen within areas or adjacent to small infarcts (Figure 1B); 
however, it was also observed, sporadically in other areas 
of pure tau pathology without clear infarction in the area. 
β-amyloid pathology within existing plaques was mainly 
separate, with mcrP-positive ‘plaque’-like material 
generally being distinct from regular ad plaques, in 
Table i: Patient information
Sample iD Age Gender Braak-nFT CeRAD infarction
496t 84 F 2.3 - +
691F 83 M 3.4 4 +
697P 87 M 4.4 6 +
CeRAD: consortium to establish a registry for alzheimer’s disease.
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co-localising with the two proteins was approximately (15% 
based on counting of 10 × fields of view at × 100 per section 
of three sections). co-localisation of the two proteins 
mcrP and p-tau was present but generally at different 
positions within the neurons. (arrows showing dark grey 
staining) (Figure 1e). 
toxic tau fibrils (neurofibrillary tangles) were present 
in some of the most degenerated regions and there was 
evidence of co-localization of p-tau. Limitations of this 
‘case study’ analysis are clearly from the small numbers 
of sections and patients reviewed. in addition, the relative 
relatively normal looking tissue regions. However, adjacent 
to previously infarcted regions some of the plaques 
(approximately 10% based on counting of 10 × fields of 
view at × 100 per section of three sections) contained a 
combination of the two proteins (Figure 1c).
p-Tau Staining and Co-localization: the majority of 
infarcted areas also exhibited other typical ad pathology 
like tau deposits. Most of the mcrP co-localized primarily 
with tau within neurons in peri-nuclear regions (Figure 
1d), although, again, the majority of neurons were either 
p-tau or mcrP positive however the number of neurons 
Figure 1: A) Single staining for monomeric c-reactive protein (mcrP)-showing increased expression within a micro-infarcted area 
(brown, arrows) (mcrP; x100), B) double labelled sections from previously infarcted regions of white (i) and grey (ii) matter showing 
co-localization of β-amyloid (blue-grey) with mcrP (brown) (iHc; x200), C) double staining for β-amyloid and mcrP showing (i) 
β-amyloid-positive (brown) and mcrP-positive (blue-grey) separate plaques in none-infarcted regions (ii) a plaque containing both 
proteins within a previously infarcted area (arrows) (iHc; x100) (inset x 200) (i) and x 200 (ii)). D) double staining co-localization 
within micro-infarcted areas of p-tau (brown) and mcrP (blue-grey) (i) an isolated double-labelled neuron (iHc; x100; inset x 200) 
and (ii) neurodegenerative grey matter with separately stained neurons for mcrP (blue-grey) and p-tau (arrows). e) double staining 
showing co-localization of amyloid and mcrP (blue-grey)-nFts-p-tau (brown) in an infarcted grey matter brain region. (i) areas of co-
localization are shown by arrows (iHc; x200). 
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timing of events in these patients e.g. infarction versus ad 
symptoms is not known and so the relative influence of one 
process on the other is subjective.
DiSCUSSiOn
Significant expression of mcrP was found adjacent to 
infarcted areas. this is in line with our previously published 
observation and hypothesis of a direct link between mcrP 
deposition and vascular damage in the brain linking it to 
subsequently and chronically hypo-perfused tissue regions 
(1). Since mcrP was also found in smaller quantities, 
in areas that were not directly associated with previous 
infarction, the expression of mcrP is likely to be due to 
de novo synthesis similar to that seen by Strang et al (3), 
however, within blood vessel walls, mcrP could infiltrate 
directly from the circulation through damaged intimal 
linings in patients with vascular disease. 
β-amyloid deposition may increase in damaged areas 
because of chronic inflammation after stroke associated 
with chronic cerebrovascular dysfunction, and this could 
be perpetuated at least in part by the presence of excessive 
mcrP (7-9). Similarly, build-up of β-amyloid is known 
to induce neuro-inflammation directly, thus potentially 
perpetuating the neurodegenerative consequences (6). 
Since mcrP is known to stimulate aberrant angiogenesis 
(2), this expression could have a potential negative influence 
on existing or neo-microvessel function and patency 
contributing to production of a local hypo-perfused 
neurodegenerative-friendly environment. 
Localization of mcrP with phosphorylated tau in neurons 
could have physiological significance. others and ourselves 
have demonstrated that mcrP can phosphorylate tau (Ser 
202,396) directly in vitro (2, 10), possibly by a mechanism 
involving gSK3β. it is worthy of note that whilst co-
localising, the two proteins mcrP and p-tau were present 
generally at different positions within the neurons. 
However, this still suggests that mcrP could contribute to 
abnormal activation of these neurons after stroke (2). 
in summary, mcrP was not found in normal-looking 
brain tissue of none dementia patients, however it is 
produced and laid down in large quantities within the 
brain following stroke, other brain injury or conditions 
linked with neuro-inflammation. given its strong aberrant 
biological properties associated with neurodegenerative 
signalling, vascular modulation and angiogenesis, and its 
direct perpetuation of inflammatory responses, a clear role 
for this protein in promoting ad and Vad is proposed (11). 
the findings shown here strengthen this hypothesis further 
providing case studies of ad patients where vascular 
insults probably linked to a local hypoxic environment 
appear to be highlighted by a strong deposition of mcrP 
and concomitant disproportionate evidence of localised 
neurodegenerative disease. Since the majority of patients 
who suffer serious stroke go on to develop cognitive decline, 
lower executive function, and psychomotor processing 
speed; and over 10% ad within 5 years (12, 13), further 
research should study potential mechanisms linking the 
two conditions with a view to creating protective novel 
therapeutics.  
COnFliCT of inTeReST 
the authors declare no conflict of interest.
SOURCe of FUnDinG
this work was supported by the research centre of 
Healthcare Science at Manchester Metropolitan University, 
and by Sheikh abdullah bin abdul Mohsen al-tuwaijri 
project grants within, Majmaah University, Saudi arabia.
ACKnOWleDGeMenT
We would like to thank the South West dementia Brain 
Bank (SWdBB) for providing brain tissue for this study. 
the SWdBB is part of the Brains for dementia research 
programme, jointly funded by alzheimer’s research UK 
and alzheimer’s Society and is supported by Brace (Bristol 
research into alzheimer’s and care of the elderly) and the 
Medical research council. this research was supported 
by Sheikh abdullah bin abdul Mohsen al-tuwaijri 
project grants within, Majmaah University, Saudi arabia. 
the authors would like to express their gratitude towards 
Sheikh abdullah abdul Mohsen al-tuwaijri, rector dr. 
Khalid Saad al Muqrin for providing the necessary support 
and assistance in completing this piece of work.
ReFeRenCeS
1. Slevin M, Matou-nasri S, turu M, Luque a, rovira n, Badimon 
L, Boluda S, Potempa L, Sanfeliu c, de Vera n, Krupinski J. 
Modified c-reactive protein is expressed by stroke neovessels 
and is a potent activator of angiogenesis in vitro. Brain Pathol. 
2010;20:151-65. 
2. Slevin M, Matou S, Zeinolabediny Y, corpas r, Weston r, Liu d, 
Boras e, di napoli M, Petcu e, Sarroca S Popa-Wagner a, Love, 
S, Font Ma, Potempa La, al-baradie r, Sanfeliu c, revilla S, 
Badimon L, and Krupinski J. Monomeric c-reactive protein-a key 
molecule driving development of alzheimer’s disease associated 
with brain ischaemia? Sci rep. 2015;5:13281.
29
Turkish Journal of PathologySLevin M et al: mCRP expression in AD   
vol. 33, No. 1, 2017; Page 25-29
8. thiele Jr, Habersberger J, Braig d, Schmidt Y, goerendt K, 
Maurer V, Bannasch H, Scheichl a, Woollard KJ, von dobschütz 
e, Kolodgie F, Virmani r, Stark gB, Peter K, eisenhardt SU. 
dissociation of pentameric to monomeric c-reactive protein 
localizes and aggravates inflammation: in vivo proof of a powerful 
proinflammatory mechanism and a new anti-inflammatory 
strategy. circulation. 2014;130:35-50. 
9. Humpel c. chronic mild cerebrovascular dysfunction for 
alzheimer’s disease? exp gerentol. 2011;46:225-32. 
10. guo H, Wang H, Wang c, cheng Y, Zou Z, Li Y, Wu J, Xu J. 
c-reactive protein induces tau Hyperphosphorylation via 
gSK3β Signalling Pathway in SH-SY5Y cells. J Mol neurosci. 
2015;56:519-27. 
11. Slevin M, Krupinski J. a role for monomeric c-reactive protein 
in regulation of angiogenesis, endothelial cell inflammation 
and thrombus formation in cardiovascular disease? Histol 
Histopathol. 2009;24:1473-8. 
12. desmond dW, Moroney Jt,Sano M, Stern Y. incidence of 
dementia after ischemic stroke: results of a longitudinal study. 
Stroke. 2002;33:2254-62. 
13. Mandzia JL, Smith ee, Horton M, Hanly P, Barber Pa, godzwon 
c, donaldson e, asdaghi n, Patel S, coutts SB. imaging and 
baseline predictors of cognitive performance in minor ischemic 
stroke and patients with transient ischemic attack at 90 days. 
Stroke. 2016;47:726-31. 
3. Strang F, Scheichl a, chen Yc, Wang X, Htun nM, Bassler 
n, eisenhardt SU, Habersberger J, Peter K. amyloid plaques 
dissociate pentameric to monomeric c-reactive protein: a novel 
pathomechanism driving cortical inflammation in alzheimer’s 
disease? Brain Pathol. 2012;22:337-46. 
4. Montagne a, nation da, Pa J, Sweeney Md, toga aW, Zlokovic 
BV. Brain imaging of neurovascular dysfunction in alzheimer’s 
disease. acta neuropathol. 2016;131:687-707. 
5. toledo JB, arnold Se, raible K, Brettschneider J, Xie SX, 
grossman M, Kukull Wa, trojanowski JQ. contribution of 
cerebrovascular disease in autopsy confirmed neurodegenerative 
disease cases in the national alzheimer’s coordinating centre. 
Brain. 2013;136:2697-706. 
6. Hyman Bt, Phelps cH, Beach tg, Bigo eH, cairns nJ, carrillo 
Mc, dickson dW, duyckaerts c, Frosch MP, Masliah e, Mirra 
SS, nelson Pt, Scneider Ja, thal dr, thies B, trojanowski JQ, 
Vinters HV, Montine tJ. national institute on aging-alzheimer’s 
association guidelines for the neuropathologic assessment of 
alzheimer’s disease. alzheimer’s dementia. 2012;8:1-13. 
7. Mccaulley Me, grush Ka. alzheimer’s disease: exploring 
the role of inflammation and implications for treatment. int J 
alzheimers dis. 2015;2015:515248. 
